Powerful efficacy through its dual mechanism of action (DNMT 1 inhibition + DNA damage repair inhibition)
Has stable PK profile, as NTX-301 is less metabolized by Decitabine's metabolic enzyme (Cytidine Deaminase)
NTX-301 is a nucleoside-based DNMT1 inhibiting targeted anticancer therapy for various blood cancers/solid cancers caused by abnormalities in DNA methyl-transferase (DNMT) that regulates the gene expression patterns in our body. The indications are MDS (myelodysplastic syndrome), AML (acute myeloid leukemia), T-ALL (T-cell acute lymphocytic leukemia) among blood cancers, and ovarian and bladder cancers among solid cancers.
Unlike the existing DNMT1 inhibitors, which are effective only in blood cancers, NTX-301 shows excellent efficacy in various solid cancers.
MDS/AML occur more often in the elderly, the sector of population, who have limited treatment options. Their 5-year survival rate is below 15%. 30~40% of T-ALL patients relapse, have limited treatment options, and have poor prognosis.
Erythrocyte
Neutrophil
Lymphocyte
Monocyte
Platelet
MDS/AML 5-Year Survival Rate (>65 Years Old)
Relapsed T-ALL Patient Overall Survival Rate
Ovarian/Bladder Cancer have serious resistance issues and low overall survival rate.
Worldwide Incidences and Deaths of Ovarian Cancer
5-Year Survival Rate of Platinum-resistant Ovarian Cancer
Worldwide Incidences and Deaths of Bladder Cancer
Overall Survival Rate of Platinum-resistant Bladder Cancer
Powerful efficacy through its dual mechanism of action (DNMT 1 inhibition + DNA damage repair inhibition)
Has stable PK profile, as NTX-301 is less metabolized by Decitabine's metabolic enzyme (Cytidine Deaminase)
Improved safety profile compared to current DNMT1 inhibitors through its selective action in cancer cells
Increased dosage enables enhanced treatment effect compared to other treatments
Oral administration that allows ease of use
Pipeline | Indication |
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
|
---|---|---|
NTX-301 | Blood Cancer (MDS/AML) |
US - Single Agent (UAB)
|
Blood Cancer (T-ALL) |
US - Single Agent (UAB)
|
|
Solid Tumor (MEN 1 Syndrome, etc.) |
US - Single Agent (NCI)
|
|
Solid Tumor (Ovarian/Bladder) |
AUS - Combi (SOCRU, etc.)
|